DaVita HealthCare Partners Reaches New 1-Year High at $70.68 (DVA)
DaVita HealthCare Partners (NYSE:DVA) shares reached a new 52-week high during trading on Friday , AmericanBankingNews.com reports. The company traded as high as $70.68 and last traded at $70.35, with a volume of 371,693 shares. The stock had previously closed at $69.90.
A number of analysts have recently weighed in on DVA shares. Analysts at Deutsche Bank reiterated a “buy” rating on shares of DaVita HealthCare Partners in a research note on Friday, May 2nd. They now have a $77.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of DaVita HealthCare Partners in a research note on Friday, May 2nd. They now have a $73.00 price target on the stock. Finally, analysts at Piper Jaffray raised their price target on shares of DaVita HealthCare Partners from $73.00 to $76.00 in a research note on Friday, May 2nd. They now have an “overweight” rating on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $83.25.
The stock’s 50-day moving average is $68.47 and its 200-day moving average is $65.43. The company has a market cap of $15.068 billion and a price-to-earnings ratio of 19.11.
DaVita HealthCare Partners (NYSE:DVA) last released its earnings data on Thursday, May 1st. The company reported $0.85 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.86 by $0.01. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.02 billion. During the same quarter in the prior year, the company posted $1.84 earnings per share. The company’s quarterly revenue was up 7.5% on a year-over-year basis. Analysts expect that DaVita HealthCare Partners will post $3.66 EPS for the current fiscal year.
In other DaVita HealthCare Partners news, COO Dennis Kogod sold 18,750 shares of the company’s stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $67.30, for a total value of $1,261,875.00. Following the completion of the sale, the chief operating officer now directly owns 40,874 shares of the company’s stock, valued at approximately $2,750,820. The sale was disclosed in a document filed with the SEC, which is available at this link.
DaVita HealthCare Partners Inc, formerly DaVita Inc, is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (NYSE:DVA).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.